5:11 PM
 | 
Apr 16, 2013
 |  BC Extra  |  Company News

Second complete response for Levadex

Allergan Inc. (NYSE:AGN) said FDA issued a complete response letter for a resubmitted NDA for Levadex dihydroergotamine for the acute treatment of migraines in adults. The company said it has already addressed the main issues raised by FDA...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >